Clinical implication of altered expression of Mad1 protein in human breast carcinoma

Cancer

Volumn 88, Issue 7, 2000, Pages 1623-1632

  Han, Sehwan ^a   Park, Kyeongmee ^a   Kim, Hong Yong ^a   Lee, Myung Soo ^a   Kim, Hong Joo ^a   Kim, Young Duck ^a   Yuh, Young Jin ^a   Kim, Sung Rok ^a   Suh, Hyun Suk ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Differentiation; Myc; Prognosis; Proliferation

Indexed keywords

HELIX LOOP HELIX PROTEIN; ONCOPROTEIN; PROTEIN MAD1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST LESION; CANCER CELL; CANCER INVASION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; ONCOGENE MYC; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARRIER PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; TIME FACTORS;

EID: 0034176239     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000401)88:7<1623::AID-CNCR17>3.0.CO;2-W     Document Type: Article

References (32)

1. Ayer DE, Kretzner L, Eisenman RN. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 1993;72:211-22.
2. Ayer DE, Eisenman RN. A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes Dev 1993;7:2110-9.
3. Blackwood EM, Kretzner L, Eisenman RN. Myc and Max function as a nucleoprotein complex. Curr Opin Genet Dev 1992;2:227-35.
4. Kretzner L, Blackwood EM, Eisenman RN. The Myc and Max proteins possess distinct transcriptional activities. Nature 1992;359:426-9.
5. Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 1992;359:423-.
6. Hurlin PJ, Foley KP, Ayer DE, Eisenman RN, Hanahan D, Arbeit JM. Regulation of Myc and Mad during epithelial differentiation and HPV-associated tumorigenesis. Oncogene 1995;11:2487-501.
7. Zornig M, Evans GI. On target with Myc. Curr Biol 1996;6: 1553-6.
8. Han S, Park K, Kim HY, Lee MS, Kim HJ, Kim YD. Expression of Mad1 protein inhibits proliferation of cancer cells and inversely correlated with Myc protein expression in primary gastric cancer. Oncol Rep 1999;6:569-74.
9. Han S, Yun IJ, Noh DY, Choe KJ, Song SY, Chi JG. Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol 1997;65:22-7.
10. Chin L, Schreiber-Agus N, Pellicer I, Chen K, Lee HW, Dudast M, et al. Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. Proc Natl Acad Sci USA 1995;92:8488-92.
11. Delgado MD, Lerga A, Canelles M, Gomez-Casares MT, Leon J. Differential regulation of Max and role of c-Myc during erythroid and myelomonocytic differentiation of K562 cells. Oncogene 1995;10:1659-65.
12. Larsson LG, Pettersson M, Oberg F, Nilsson K, Luscher B. Expression of mad, mxil, max, and c-myc during induced differentiation of hematopoietic cells: opposite regulation of mad and c-myc. Oncogene 1994;9:1247-52.
13. Vastrik I, Kaipainen A, Penttila TL, Lymboussakis A, Alitalo R, Parvinen M, et al. Expression of the mad gene during cell differentiation in vivo and its inhibition of cell growth in vitro. J Cell Biol 1995;128:1197-208.
14. Koskinen PJ, Ayer DE, Eisenman RN. Repression of Myc-Ras co-transformation by Mad is mediated by multiple protein-protein interactions. Cell Growth Diff 1995;6:623-9.
15. Ayer DE, Laherty CD, Lawrence QA, Armstrong AP, Eisenman RN. Mad protein contain a dominant transcription repression domain. Mol Cell Biol 1996;16:5772-81.
16. Cemi C, Bousset K, Seelos C, Burkhardt H, Henriksson M, Luscher B. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins. Oncogene 1995;11:587-96.
17. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991;251:1211-7.
18. Luscher B, Eisenman RN. New light on Myc and Myb. Part I. Myc. Genes Dev 1990;4:2025-35.
19. DePinho RA, Schreiber-Agus N, Alt FW. myc family oncogenes in the development of normal and neoplastic cells. Adv Cancer Res 1991;57:1-46.
20. Marcu KB, Bossone SA, Patel AJ. myc function and regulation. Ann Rev Biochem 1992;61:809-60.
21. Blackwood EM, Luscher B, Eisenman RN. Myc and Max associate in vivo. Genes Dev 1992;6:71-80.
22. Meichle A, Phillipp A, Eilers M. The functions of Myc proteins. Biochim Biophys Acta 1992;1114:129-46.
23. Henriksson M, Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res 1996;68:109-82.
24. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-28.
25. Hanson KD, Shichiri M, Follansbee MR, Sedivy JM. Effects of c-myc expression on cell cycle progression. Moll Cell Biol 1994;14:5748-55.
26. Nguyen HQ, Selvakumaran M, Lieberman DA, Huffman B. Blocking c-Myc and Max expression inhibits proliferation and induces differentiation of normal and leukemic myeloid cells. Oncogene 1995;11:2439-44.
27. Paradiso A, Mangia A, Barletta A, Fusilli S, Marzullo F, Schttulli F, et al. Heterogeneity of intratumour proliferative activity in primary breast cancer: biological and clinical aspects. EurJ Cancer 1995;31A:911-6.
28. Dubik D, Shiu RPC. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 1992;7:1587-94.
29. Le Roy X, Escot C, Brouillet JP, Theillet C, Maudelonde T, Simony-Lafontaine J, et al. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer. Oncogene 1991;6:431-7.
30. Musgrove EA, Hamilton JA, Lee CSL, Sweeney KJE, Watts CKW, Sutherland RL Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993;13:3577-87.
31. Vink-van Wijngaarden T, Pols HAP, Buurman CJ, van den Bemd GJCM, Dorssers LCJ, Birkenhager JC, et al. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res 1994;54: 5711-7.
32. Wilken NRC, Sarcevic B, Musgrove EA, Sutherland RL. Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells. Cell Growth Diff 1996;7:65-74.